Financial Data and Key Metrics Changes - Revenue for Q1 2024 grew 39% year-over-year to $16.6 million, marking the 13th consecutive quarter of growth of 35% or greater [7][94] - Gross margin increased to 68% from 66% in the prior year, primarily due to improved inventory management [82] - Operating loss decreased to $4.8 million from $11.3 million in the prior year, with net loss reduced to $5.7 million from $12 million [70] Business Line Data and Key Metrics Changes - OviTex revenue grew 31%, while OviTex PRS saw a 54% increase in the same period, driven by higher unit sales and expansion of the commercial organization [7][96] - PRS now accounts for over a third of total sales, with the long-term resorbable configuration making up 55% of the PRS portfolio [96] Market Data and Key Metrics Changes - The company engaged with surgeons at 25 industry meetings through March 2024, enhancing its presence in the market [20] - Over 50,000 units of OviTex have been used in hernia and complex abdominal wall procedures, indicating strong market penetration [96] Company Strategy and Development Direction - The company aims to capitalize on the momentum generated in Q4 2023, focusing on product launches and enhancements to the commercial team [4] - TELA Bio is positioned to compete effectively with larger competitors, leveraging a complete product portfolio and strong clinical data [67][100] Management's Comments on Operating Environment and Future Outlook - Management expects operating loss and net loss to decrease in 2024 compared to 2023, with steady operating expenses and sequential revenue growth [8] - The company is optimistic about the potential of LIQUIFIX and IHR products to open new market opportunities [9][12] Other Important Information - The company ended Q1 2024 with $37.1 million in cash and cash equivalents, indicating a strong financial position [70] - A strategic hire was made with Dr. Howard Langstein joining as Vice President of Medical Affairs to drive awareness of TELA's products [62] Q&A Session Summary Question: How do you feel about cash burn this quarter and how you expect that to trend throughout the year? - Management expressed confidence in cash burn management, anticipating steady operational expenses and revenue growth to improve profitability metrics [48] Question: Can you provide an update on your GPO contracts and how you're ramping there? - The company is actively pursuing access via IDNs and smaller GPOs, with positive dynamics expected for future contracts [107][119] Question: What are the sequential expectations for Q2? - Management noted that Q2 is typically a strong quarter and expressed optimism about growth driven by a fully staffed sales organization and new product introductions [44] Question: How is productivity trending, including initiatives for balanced selling? - New reps are averaging just under six months to reach breakeven, with a balanced selling approach showing early signs of success [47][29] Question: What is the contribution expected from IHR for this year? - IHR is anticipated to have a quick uptake among surgeons already using TELA's products, contributing positively to revenue [105] Question: Can you elaborate on the impact of the synthetic mesh lawsuit? - Management is monitoring the situation closely and has a communication plan in place to address potential outcomes [71][86]

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or othe ...

Exhibit 99.1 Recent Highlights "We've begun 2024 with strong momentum led by a maturing sales force, strategic product portfolio launches, and sustained market share growth across our OviTex portfolio," said Antony Koblish, co-founder, President, and Chief Executive Officer of TELA Bio. "TELA Bio is focused on optimizing this growth phase, driving our sales force towards a more balanced selling approach across the Hernia and PRS franchises, generating increasing operating leverage over time, and continuing ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Conference Call March 21, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Antony Koblish - Co-Founder, President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Michael Sarcone - Jefferies David Turkaly - JMP Securities Operator Good afternoon ladies and gentlemen and welco ...

Fourth Quarter 2023 Financial Results Revenue was $17.0 million in the fourth quarter of 2023, an increase of 46% compared to the same period in 2022. The increase was due to an increase in unit sales of our products and the continued expansion of the commercial organization, which resulted in increased penetration of existing customer accounts, the addition of new customers, and growing international sales. Gross profit was $11.6 million in the fourth quarter of 2023, or 68% of revenue, compared to $8.2 mi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or ...

TELA Bio, Inc. (NASDAQ:TELA) Q3 2023 Earnings Call Transcript November 9, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and Chief Executive Officer Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O’Brien - Piper Sandler Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Operator Good day and thank you for standing by, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other ...

TELA Bio, Inc. (NASDAQ:TELA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Louisa Smith – Gilmartin Group Tony Koblish – President and Chief Executive Officer Roberto Cuca – Chief Operating Officer and Chief Financial Officer Conference Call Participants Michael Sarcone – Jefferies Frank Takkinen – Lake Street Capital Markets David Turkaly – JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2023 Earnings Conference Call ...